CLSA was recently featured in BioWorld, regarding the growth of California’s life sciences industry.
CLSA was recently featured in the San Diego Union-Tribune, discussing the growth of the San Diego County life sciences innovation ecosystem.
Congress is currently advancing legislation in both chambers to significantly overhaul the U.S. tax code. Historically, CLSA has focused our tax-related advocacy efforts around: (1) calling for an update and making permanent of the R&D Tax Credit, (2) protecting the Orphan Drug Tax Credit (ODTC), and (3) opposing the creation of and later calling for a repeal of the medical device tax.
Shortly before Thanksgiving, California’s Office of Statewide Health Planning and Development (OSHPD) released its implementation plan for Senate Bill 17 (Hernandez). The bill was signed into law in October, and its advance notice provisions take effect on Jan. 1, 2018.
California Life Sciences Association (CLSA) and PwC US newly released annual California Life Sciences Industry Report, provides a snapshot of the largest life sciences cluster in the world. The 2018 report shows that California continues to outpace other states in life science-related economic growth, including venture funding, National Institutes of Health (NIH) funding, digital health venture funding, and is producing nearly 300,000 jobs and shepherding more than a thousand new therapies through the pipeline.
For over 7 years, CLSA has advocacted for repeal of IPAB because such blunt cost containment approaches could seriously harm the delicate cycle of biomedical innovation by reducing incentives for investment in new research and product development, and ultimately limit patient access to lifesaving treatments, therapies and technologies.
Despite the best efforts of CLSA and its partner trade associations, both Senate Bill 17 (Hernandez) and Assembly Bill 265 (Wood) reached the Governor’s desk and were signed into law.
On Oct. 12, the National Institutes of Health (NIH) announced a new partnership with 11 biopharmaceutical companies aimed at accelerating innovation in new cancer immunotherapy therapies. Nine of the 11 companies are CLSA members: AbbVie; Amgen; Boehringer Ingelheim Pharma GmbH & Co. KG; Bristol-Myers Squibb; Celgene Corporation; Genentech, a member of the Roche Group; Gilead Sciences; Janssen Pharmaceutical Companies of Johnson & Johnson; and Pfizer, Inc.
Esteemed Industry Leaders to be Honored for Contributions to California’s Thriving Life Sciences Sector on Nov. 10
The Pantheon Awards program, now in its 14th year, brings together more than 600 industry pioneers – including innovators, thought leaders, investors and educators